ProCE Banner Activity

What I Want My Colleagues to Know About State-of-the-Art Biomarker Testing for GI Malignancies

Clinical Thought
In this commentary, an expert summarizes current and emerging uses of biomarker testing to guide therapy for patients with gastrointestinal cancers, including colorectal cancer, gastric cancer, and cholangiocarcinoma.

Released: April 27, 2022

Expiration: April 26, 2023

No longer available for credit.

Share

Faculty

Christopher H. Lieu

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Pfizer, Inc.

Seagen Inc.

Partners

American Society for Clinical Pathology

ProCE Banner

Faculty Disclosure

Primary Author

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Christopher H. Lieu, MD, has disclosed that he has received funds for research support from Merck and consulting fees from Natera.